Pacira BioSciences
PCRX
260 hedge funds and large institutions have $1.21B invested in Pacira BioSciences in 2025 Q4 according to their latest regulatory filings, with 49 funds opening new positions, 87 increasing their positions, 92 reducing their positions, and 25 closing their positions.
293% more call options, than puts
Call options by funds: $2.5M | Put options by funds: $638K
96% more first-time investments, than exits
New positions opened: 49 | Existing positions closed: 25
9% more funds holding
Funds holding: 239 → 260 (+21)
2.35% more ownership
Funds ownership: 106.76% → 109.11% (+2.4%)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
2% less capital invested
Capital invested by funds: $1.24B → $1.21B (-$21.3M)
5% less repeat investments, than reductions
Existing positions increased: 87 | Existing positions reduced: 92
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$17.8M |
| 2 |
HIM
Hillsdale Investment Management
Toronto,
Ontario, Canada
|
+$7.33M |
| 3 |
Jane Street
New York
|
+$5.69M |
| 4 |
Two Sigma Investments
New York
|
+$5.2M |
| 5 |
LSV Asset Management
Chicago,
Illinois
|
+$4.89M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Balyasny Asset Management
Chicago,
Illinois
|
-$22.3M |
| 2 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
-$11.5M |
| 3 |
Adage Capital Partners
Boston,
Massachusetts
|
-$10.6M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
-$9.15M |
| 5 |
UBS Group
Zurich,
Switzerland
|
-$7.04M |
PCRX Hedge Fund Activity: Q4 2025 in Review
260 of the 8,267 institutional investors tracked by Wall St. Rank reported a position in Pacira BioSciences (PCRX) for Q4 2025, worth a combined $1.21B — down 1.7% from $1.24B a quarter earlier.
Buyers outnumbered sellers: 49 funds opened new PCRX positions and 25 closed out — a net gain of 24 holders — while 87 added to existing stakes and 92 trimmed.
The largest buyer was Citadel Advisors, adding an estimated $17.8M. The largest seller was Balyasny Asset Management, cutting an estimated $22.3M.
- 260 institutional investors held Pacira BioSciences (PCRX) as of Q4 2025, up from 239 in Q3 2025.
- Funds reported $1.21B of Pacira BioSciences stock for Q4 2025, down 1.7% quarter-over-quarter.
- 49 funds opened new Pacira BioSciences positions in Q4 2025 and 25 closed out, a net change of +24 holders.
- The largest Pacira BioSciences buyer in Q4 2025 was Citadel Advisors, an estimated $17.8M added.
- The largest Pacira BioSciences seller in Q4 2025 was Balyasny Asset Management, an estimated $22.3M sold.
Based on aggregated 13F filings for Q4 2025.